Small-cell lung cancer is among the most aggressive malignancies encountered in clinical practice, and its standard treatment with etoposide-platinum chemotherapy carries a well-known hazard: chemotherapy-induced febrile neutropenia, a potentially life-threatening complication in which the immune system’s white-cell defenses collapse and fever signals a serious infection. International guidelines from ESMO, EORTC and ASCO have long recommended primary prophylaxis with granulocyte colony-stimulating factor, or G-CSF, for patients whose chemotherapy regimen carries a high risk of febrile neutropenia or who have additional patient-related risk factors. Yet a large new analysis of real-world French practice, published in Supportive Care in Cancer, suggests that this protective measure reaches only about two-thirds of the patients who should be receiving it according to those very guidelines.
The study, led by L. Falchero of the Hopitaux Nord-Ouest respiratory medicine department in Villefranche-sur-Saone, drew on the prospective national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG, which captured patients newly diagnosed with lung cancer in 2020 and treated in non-academic public hospitals across France. Because these cohorts were designed to enroll consecutive patients nationwide rather than selected referral cases, they offer an unusually faithful snapshot of everyday oncology, in contrast to the carefully curated populations of randomized trials. From a total of 527 patients with small-cell lung cancer, the investigators applied predefined eligibility criteria for G-CSF primary prophylaxis, based on the febrile neutropenia risk of each chemotherapy regimen and on patient-related risk factors, in line with guideline recommendations.
The headline finding is stark in its simplicity. Of the 527 patients, 447, or 84.8 percent, met the predefined eligibility criteria for G-CSF primary prophylaxis. Yet among those eligible patients, only 285, or 63.8 percent, actually received the prophylaxis. In other words, roughly one in three patients for whom guidelines would have supported preventive G-CSF treatment did not get it. A sensitivity analysis, designed to test whether the eligibility definition itself drove the result, confirmed the picture: 439 patients remained eligible under the alternative assumptions, and 281 of them, or 64.0 percent, received prophylaxis, a proportion essentially unchanged from the primary analysis.
Perhaps the most revealing part of the study lies in who did and did not receive the treatment. Patients given G-CSF primary prophylaxis were significantly younger than those who were not, with a mean age of 66.4 years versus 69.4 years, a difference that reached statistical significance at p less than 0.001. Performance status, a standardized measure of a patient’s functional fitness, also separated the groups sharply: 76.3 percent of the prophylaxis group had a good performance status of 0 or 1, compared with 56.0 percent of the non-prophylaxis group, a difference significant at p less than 0.0001. These patterns hint at a systematic bias in prescribing, in which fitter, younger patients are preferentially offered the protective therapy while older and frailer patients, who may in fact be at higher risk of severe complications from febrile neutropenia, are left without it.
The biology behind the recommendation is worth unpacking. G-CSF is a growth factor that stimulates the bone marrow to produce neutrophils, the white blood cells that form the first line of defense against bacterial and fungal infections. Intensive chemotherapy regimens such as carboplatin or cisplatin combined with etoposide, the backbone of small-cell lung cancer treatment, suppress the marrow profoundly, and the resulting nadir in neutrophil counts typically occurs one to two weeks after each cycle. When fever develops during this window of profound neutropenia, mortality and intensive-care admission rates rise substantially, and prior studies cited by the authors have documented both the incidence of febrile neutropenia in chemotherapy-naive lung cancer patients receiving etoposide plus platinum and the risk factors that predict it, including older age and poor performance status.
Prophylaxis given before the first chemotherapy cycle, so-called primary prophylaxis, is intended to blunt that nadir before it happens, rather than reacting after a first febrile episode. Beyond preventing infections, maintaining the neutrophil count also helps preserve chemotherapy dose intensity, the ability to deliver each planned cycle on schedule and at full dose, which a systematic review and meta-analysis by Lyman and colleagues linked to cancer outcomes. Japanese studies and a 2022 systematic review and meta-analysis published in International Journal of Clinical Oncology have specifically examined the effectiveness and safety of G-CSF primary prophylaxis in lung cancer, supporting its role in this population. French national thoracic oncology guidelines, most recently updated in 2025 by the Auvergne-Rhone-Alpes ARISTOT group, similarly codify when prophylaxis should be offered.
Against that backdrop, the descriptive survival data from the French cohorts are intriguing but must be read with caution, as the authors themselves emphasize. Among patients eligible for primary prophylaxis, median overall survival was 11.2 months in the group that received it, with 3-month and 6-month overall survival of 89.8 percent and 75.4 percent, compared with 8.4 months and 72.8 percent and 63.0 percent respectively in the group that did not. Progression-free survival showed a similar early separation, with 3-month and 6-month rates of 86.7 percent and 56.1 percent in the prophylaxis group versus 70.4 percent and 51.2 percent in the non-prophylaxis group. However, the authors are explicit that these estimates are descriptive only: there were baseline imbalances between the groups, and the survival curves cross at around 12 months, meaning the apparent early advantage cannot be interpreted causally. Sicker patients received less prophylaxis, and sicker patients also die sooner, a classic confounding pattern that no observational analysis of this design can untangle.
The finding of incomplete guideline implementation is not unique to France. A German representative survey published in Supportive Care in Cancer documented gaps in G-CSF guideline adherence among German oncology practices, and a Moroccan single-center experience likewise reported variable use of primary prophylaxis. Physician preference studies add another layer of complexity: a discrete-choice experiment published in BMJ Supportive and Palliative Care found that French physicians weigh factors beyond clinical risk when deciding on febrile neutropenia prophylaxis, and a 2024 questionnaire study on outpatient G-CSF prescribing concluded that considerations beyond clinical factors shape real-world decisions. Practical barriers, including injection logistics, cost concerns, and the perception that elderly or frail patients derive less benefit, likely all contribute to the shortfall observed in the French data.
The therapeutic landscape of small-cell lung cancer has also shifted in ways that raise the stakes of supportive care. The landmark IMpower133 and CASPIAN phase 3 trials established chemoimmunotherapy, combining platinum-etoposide with atezolizumab or durvalumab, as the new first-line standard for extensive-stage disease, and the KBP-ESCAP cohort program itself has documented the impact of immunotherapy on real-life survival in France. In this era, avoiding treatment delays and dose reductions caused by neutropenic complications matters more than ever, since interruptions may compromise the delivery of both cytotoxic and immunotherapeutic components. Safety questions around G-CSF use during concurrent chemoradiotherapy in limited-stage disease, explored in secondary analyses of the CONVERT trial and in retrospective cohort studies of pegylated G-CSF, add nuance but do not negate the case for prophylaxis in patients treated with chemotherapy alone.
What the French analysis ultimately delivers is a benchmark. By quantifying, in a nationwide prospective cohort of 527 consecutive small-cell lung cancer patients, that only about 64 percent of guideline-eligible individuals received G-CSF primary prophylaxis, and by showing that the shortfall concentrates among older patients and those with poorer performance status, the study gives clinicians, hospital administrators and guideline developers a concrete target for quality improvement. The authors suggest that interventions such as electronic medical record prompts, which a 2015 study showed could influence growth factor use, might help close the gap. Whether the survival differences observed in the early months reflect genuine benefit or merely the confounding of patient selection, the message for practice is unambiguous: the decision to withhold prophylaxis should be a deliberate, guideline-informed judgment, not a default driven by age or frailty, because the patients most often left unprotected may be precisely those least able to survive a febrile neutropenic episode.
Subject of Research: Real-world use of G-CSF primary prophylaxis against febrile neutropenia in small-cell lung cancer
Article Title: Real-world use of G-CSF primary prophylaxis in small cell lung cancer: secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
Article References: Real-world use of G-CSF primary prophylaxis in small cell lung cancer: secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG. (n.d.). https://doi.org/10.1007/s00520-026-11223-7
Image Credits: AI Generated
DOI: 10.1007/s00520-026-11223-7
Keywords: small-cell lung cancer, G-CSF, primary prophylaxis, febrile neutropenia, chemotherapy, guideline adherence, real-world evidence, supportive care, etoposide-platinum, performance status, France, national cohorts
News Source: Nathaniel Bowman. (October 7, 2026). Two-Thirds of Eligible Lung Cancer Patients Miss Guideline-Backed Infection Shield, French Data Show. Scienmag.
